Organic solute transporter, OST-OST: Its role in bile acid transport and cholestasis

Seminars in Liver Disease

Volumn 30, Issue 2, 2010, Pages 178-185

  Soroka, Carol J ^a   Ballatori, Nazzareno ^b   Boyer, James L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Adaptive regulation; Bile acid homeostasis; Ileal bile acid transporter; Nuclear receptor

Indexed keywords

BILE ACID; CARRIER PROTEIN; DIGOXIN; ESTRONE SULFATE; FARNESOID X RECEPTOR; PRASTERONE SULFATE; PROSTAGLANDIN E2; PROTEIN OSTALPHA; PROTEIN OSTBETA; UNCLASSIFIED DRUG;

ADRENAL GLAND; BILE ACID SYNTHESIS; CHOLESTASIS; ELECTRIC FISH; HUMAN; KIDNEY; LEUCORAJA ERINACEA; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SMALL INTESTINE; TESTIS; TISSUE DISTRIBUTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS; ENTEROHEPATIC CIRCULATION; HOMEOSTASIS; HUMANS; KIDNEY; LIVER; MEMBRANE TRANSPORT PROTEINS; MICE; P-GLYCOPROTEINS; SUBSTRATE SPECIFICITY;

EID: 77951523553     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1253226     Document Type: Review

References (60)

1. Wong M H., Oelkers P, Craddock A L., Dawson P A. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem 1994 269 (2) 1340-1347
2. Wang W, Seward D J., Li L, Boyer J L., Ballatori N. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc Natl Acad Sci U S A 2001 98 (16) 9431-9436
3. Seward D J., Koh A S., Boyer J L., Ballatori N. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem 2003 278 (30) 27473-27482
4. Rao A, Haywood J, Craddock A L., Belinsky M G., Kruh G D., Dawson P A. The organic solute transporter -, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A 2008 105 (10) 3891-3896
5. Soroka C J., Mennone A, Hagey L, Ballatori N, Boyer J L. Organic solute transporter deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology 2010 51 181-190
6. Ballatori N, Christian W V., Lee J Y. et al. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005 42 (6) 1270-1279
7. Ballatori N, Li N, Fang F, Boyer J L., Christian W V., Hammond C L. OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Front Biosci 2009 14 2829-2844
8. Balesaria S, Pell R J., Abbott L J. et al. Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. Eur J Gastroenterol Hepatol 2008 20 (5) 413-422
9. Lee H, Zhang Y, Lee F Y., Nelson S F., Gonzalez F J., Edwards P A. FXR regulates organic solute transporters and in the adrenal gland, kidney, and intestine. J Lipid Res 2006 47 (1) 201-214
10. Dawson P A., Hubbert M, Haywood J et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005 280 (8) 6960-6968
11. Soroka C J., Xu S, Mennone A, Lam P, Boyer J L. N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta. BMC Cell Biol 2008 9 57
12. Sun A-Q, Balasubramaniyan N, Xu K et al. Protein-protein interactions and membrane localization of the human organic solute transporter. Am J Physiol Gastrointest Liver Physiol 2007 292 (6) G1586-G1593
13. Li N, Cui Z, Fang F, Lee J Y., Ballatori N. Heterodimerization, trafficking and membrane topology of the two proteins, Ost and Ost beta, that constitute the organic solute and steroid transporter. Biochem J 2007 407 (3) 363-372
14. Boyer J L., Trauner M, Mennone A et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006 290 (6) G1124-G1130
15. Frankenberg T, Rao A, Chen F, Haywood J, Shneider B L., Dawson P A. Regulation of the mouse organic solute transporter -, Ostalpha-Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol 2006 290 (5) G912-G922
16. Landrier J-F, Eloranta J J., Vavricka S R., Kullak-Ublick G A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter- and - genes. Am J Physiol Gastrointest Liver Physiol 2006 290 (3) G476-G485
17. Lu T T., Makishima M, Repa J J. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000 6 (3) 507-515
18. Denson L A., Sturm E, Echevarria W et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001 121 (1) 140-147
19. Sinal C J., Tohkin M, Miyata M, Ward J M., Lambert G, Gonzalez F J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000 102 (6) 731-744
20. Grober J, Zaghini I, Fujii H et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 1999 274 (42) 29749-29754
21. Zollner G, Wagner M, Moustafa T et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-/ in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006 290 (5) G923-G932
22. Ballatori N, Fang F, Christian W V., Li N, Hammond C L. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am J Physiol Gastrointest Liver Physiol 2008 295 (1) G179-G186
23. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005 2 (4) 217-225
24. Boyer J L. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 2007 46 (3) 365-371
25. Zollner G, Fickert P, Silbert D et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003 38 (6) 717-727
26. Schaap F G., van der Gaag N A., Gouma D J., Jansen P LM. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009 49 (4) 1228-1235
27. Keitel V, Burdelski M, Warskulat U et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005 41 (5) 1160-1172
28. Chen J, Terada T, Ogasawara K, Katsura T, Inui K-i. Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am J Physiol Renal Physiol 2008 295 (1) F247-F252
29. Zollner G, Wagner M, Fickert P et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007 27 (7) 920-929
30. Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 2000 275 (4) 2905-2910
31. Zamek-Gliszczynski M J., Nezasa K-i, Tian X et al. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 2006 319 (3) 1485-1491
32. Cui Y J., Aleksunes L M., Tanaka Y, Goedken M J., Klaassen C D. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol Sci 2009 110 (1) 47-60
33. Donner M G., Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001 34 (2) 351-359
34. Ogawa K, Suzuki H, Hirohashi T et al. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000 278 (3) G438-G446
35. Soroka C J., Lee J M., Azzaroli F, Boyer J L. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001 33 (4) 783-791
36. Belinsky M G., Dawson P A., Shchaveleva I et al. Analysis of the in vivo functions of Mrp3. Mol Pharmacol 2005 68 (1) 160-168
37. Bohan A, Chen W-S, Denson L A., Held M A., Boyer J L. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003 278 (38) 36688-36698
38. Zelcer N, van de Wetering K, de Waart R et al. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 2006 44 (4) 768-775
39. Knig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999 29 (4) 1156-1163
40. Kruh G D., Belinsky M G., Gallo J M., Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 2007 26 (1) 5-14
41. Mennone A, Soroka C J., Cai S-Y et al. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006 43 (5) 1013-1021
42. Assem M, Schuetz E G., Leggas M et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004 279 (21) 22250-22257
43. Saini S PS, Sonoda J, Xu L et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 2004 65 (2) 292-300
44. Wagner M, Halilbasic E, Marschall H-U et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005 42 (2) 420-430
45. Stedman C AM, Liddle C, Coulter S A. et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci U S A 2005 102 (6) 2063-2068
46. Huang W, Zhang J, Moore D D. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004 113 (1) 137-143
47. Yin J, Wennberg R P., Xia Y C., Liu J W., Zhou H Z. Effect of a traditional Chinese medicine, yin zhi huang, on bilirubin clearance and conjugation. Dev Pharmacol Ther 1991 16 (1) 59-64
48. Modica S, Bellafante E, Moschetta A. Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. Front Biosci 2009 14 4719-4745
49. Bloomer J R., Boyer J L. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975 82 (3) 310-317
50. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006 26 (8) 943-948
51. Schlattjan J H., Winter C, Greven J. Regulation of renal tubular bile acid transport in the early phase of an obstructive cholestasis in the rat. Nephron Physiol 2003 95 (3) 49-56
52. Stiehl A, Raedsch R, Rudolph G, Gundert-Remy U, Senn M. Biliary and urinary excretion of sulfated, glucuronidated and tetrahydroxylated bile acids in cirrhotic patients. Hepatology 1985 5 (3) 492-495
53. Knisely A S., Strautnieks S S., Meier Y et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006 44 (2) 478-486
54. Halpern M D., Dvorak B. Does abnormal bile acid metabolism contribute to NEC? Semin Perinatol 2008 32 (2) 114-121
55. Renner O, Harsch S, Strohmeyer A, Schimmel S, Stange E F. Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J Lipid Res 2008 49 (9) 2045-2054
56. Kakizaki S, Yamazaki Y, Takizawa D, Negishi M. New insights on the xenobiotic-sensing nuclear receptors in liver diseasesCAR and PXR Curr Drug Metab 2008 9 (7) 614-621
57. Rezen T, Tamasi V, Lvgren-Sandblom A, Bjrkhem I, Meyer U A., Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 2009 10 384
58. Stefano F, Sabrina C, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 2009 49 (2) 171-185
59. Lahtela J T., Arranto A J., Sotaniemi E A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 1985 34 (9) 911-916
60. Dong B, Saha P K., Huang W et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci U S A 2009 106 (44) 18831-18836